OncoMatch/Clinical Trials/NCT05305859
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
Is NCT05305859 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies venetoclax combining chidamide and azacitidine (VCA) for leukemia, myeloid, acute.
Treatment: venetoclax combining chidamide and azacitidine (VCA) — The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Kidney function
Creatinine clearance≥30 mL/min and serum Creatinine ≤ 160µmol/L
Liver function
ALT and AST ≤ 3 × upper limit of normal (ULN)
Cardiac function
No uncontrolled or significant cardiovascular disease, including: bradycardia <50 bpm (unless pacemaker), long QT syndrome, SBP ≥180 mmHg or DBP ≥110 mmHg, ventricular arrhythmias, Mobitz II or third degree heart block (unless pacemaker and no symptoms), uncontrolled angina or MI within 6 months, NYHA Class 3 or 4 heart failure, complete LBBB, LVEF ≤45% or below institutional lower limit
Adequate laboratory parameters during the screening period as evidenced by the following: Creatinine clearance≥30 mL/min and serum Creatinine ≤ 160µmol/L; ALT and AST ≤ 3 × upper limit of normal (ULN); Known history of left ventricular ejection fraction (LVEF) ≤45% or less than the institutional lower limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05305859 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify